文献速递眼底病与葡萄膜炎

BRAMD试验中抗血小板和抗凝药物不影响新生血管性年龄相关性黄斑变性的视力结局

Antiplatelet and Anticoagulant Drugs Do Not Affect Visual Outcome in Neovascular Age-Related Macular Degeneration in the BRAMD Trial.
PubMed 文献 · Am J Ophthalmol · 2018-01-09

该研究为BRAMD随机对照试验数据的回顾性分析,纳入荷兰330例活动性新生血管性年龄相关性黄斑变性患者,40.9%使用抗血小板或抗凝药物(其中73.3%为阿司匹林)。抗血小板或抗凝药物使用与视力损害(校正OR 0.79;95%CI 0.43-1.44)或严重视力损害(校正OR 0.75;95%CI 0.40-1.43)均无关联,出血频率在用药者与未用药者间无显著差异(27% vs 32%,P=.32)。结论为抗血小板或抗凝药物使用与视力下降及出血发生均无关。

要点

  • 抗血小板或抗凝药物使用与视力损害无关联(校正OR 0.79;95%CI 0.43-1.44)。
  • 抗血小板或抗凝药物使用与严重视力损害无关联(校正OR 0.75;95%CI 0.40-1.43)。
  • 用药者与未用药者出血频率无显著差异(27% vs 32%,P=.32)。

核心结论

  • 在活动性新生血管性年龄相关性黄斑变性患者中,抗血小板或抗凝药物使用与视力下降及出血发生均无关联。

研究设计与样本

  • 研究为对BRAMD随机对照试验数据的回顾性分析,该试验在荷兰比较贝伐珠单抗与雷珠单抗。
  • 研究设置:多中心。
  • 研究人群:330例活动性新生血管性年龄相关性黄斑变性患者。
  • 观察程序:患者接受全面眼科检查,视力分为功能性视力(最佳矫正视力≥0.5)、视力损害(最佳矫正视力<0.5)和严重视力损害(最佳矫正视力<0.3);眼底照片评估视网膜或视网膜下出血;通过访谈获取抗血小板或抗凝药物信息;采用逻辑回归分析关联,采用ANCOVA分析出血频率。
  • 主要结局指标:最佳矫正视力和出血存在。

主要发现

  • 40.9%的患者使用抗血小板或抗凝药物,其中73.3%为阿司匹林。
  • 抗血小板或抗凝药物使用与视力损害无关联(校正OR 0.79;95%CI 0.43-1.44)。
  • 抗血小板或抗凝药物使用与严重视力损害无关联(校正OR 0.75;95%CI 0.40-1.43)。
  • 用药者与未用药者出血频率相当(27% vs 32%,P=.32)。
  • 仅限阿司匹林使用者的分析结果相似。

关键数值与推荐

  • 功能性视力定义为最佳矫正视力≥0.5。
  • 视力损害定义为最佳矫正视力<0.5。
  • 严重视力损害定义为最佳矫正视力<0.3。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine if use of antiplatelet or anticoagulant (AP/AC) medication influences visual acuity in patients with active neovascular age-related macular degeneration (N-AMD). DESIGN: Retrospective analysis of data from a randomized controlled trial. METHODS: Setting: Multicenter. STUDY POPULATION: Total of 330 patients with active N-AMD from the BRAMD study, a comparative trial between bevacizumab and ranibizumab in the Netherlands. OBSERVATION PROCEDURES: Patients underwent an extensive ophthalmic examination. Visual acuity was categorized into functional vision (best-corrected visual acuity [BCVA] ≥ 0.5), visual impairment (BCVA < 0.5), and severe visual impairment (BCVA < 0.3). Fundus photographs were graded for presence of retinal or subretinal hemorrhages. Information on AP/AC medication was obtained through interview. Logistic regression analysis was used to determine associations between AP/AC medication and outcomes. Frequency of hemorrhages in users and non-users stratified for visual acuity categories was analyzed with ANCOVA. MAIN OUTCOME MEASURES: BCVA and presence of hemorrhages. RESULTS: In total, 40.9% of the patients used AP/AC medication, of which 73.3% was aspirin. AP/AC use was not associated with visual impairment (adjusted odds ratio [OR] 0.79; 95% confidence interval [CI] 0.43-1.44) or severe visual impairment (adjusted OR 0.75; 95% CI 0.40-1.43). Patients on AP/AC presented with comparable frequencies of hemorrhages (27% vs 32%, P = .32, respectively). Similar results were found when analyses were restricted to aspirin users only. CONCLUSION: In our study, use of AP/AC medication was associated neither with visual decline nor with the occurrence of hemorrhages in patients with active N-AMD.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Buitendijk GHS, Schauwvlieghe AME, Vingerling JR, et al. Antiplatelet and Anticoagulant Drugs Do Not Affect Visual Outcome in Neovascular Age-Related Macular Degeneration in the BRAMD Trial. Am J Ophthalmol. 2018. PMID: 29330064. doi:10.1016/j.ajo.2018.01.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。